Aiolos Bio

Aiolos Bio is dedicated to helping patients breathe easier, and we aim to redefine the treatment approach for respiratory and inflammatory diseases. Our lead candidate drug is AIO-001, a humanized anti-TSLP monoclonal antibody being developed for the treatment of moderate to severe asthma. With a long history of successful drug development in respiratory and immunological diseases, our team seeks to leverage this expertise to address the significant unmet needs of asthma patients worldwide.